International Journal of Innovative Approaches in Science Research
Abbreviation: IJIASR | ISSN (Print): 2602-4810 | ISSN (Online): 2602-4535 | DOI: 10.29329/ijiasr

Original article    |    Open Access
International Journal of Innovative Approaches in Science Research 2018, Vol. 2(1) 25-40

Effects of Salinomycin and Everolimus on Breast Cancer Stem Cells in Hypoxia

Hatice Pilevneli & Mehtap Kılıç Eren

pp. 25 - 40   |  DOI:

Published online: March 29, 2018  |   Number of Views: 299  |  Number of Download: 918


Cancer stem cells (CSCs) are a collection of small numbers of cells that have the potential to induce all cell types within the tumor mass and have self-renewal capacity. Today, the reasons for the failure of conventional cancer therapies lie in the fact that they are unable to target cancer stem cells. Targeting the cancer stem cell is thought to provide a very important and revolutionary advance in cancer cell targeting and therapy

 Tumor hypoxia is a characteristic of solid tumors and has been associated with poor prognosis and resistance to radiotherapy and chemotherapy. HIF-1 (Hypoxia Inducible Factor-1) is the major transcription factor activated in hypoxic conditions and allows transcriptional activation of various genes that are effective for the adaptation of the cell to the hypoxic condition. Experimental studies have provided evidence that also hypoxia and HIF-1α promote the cancer stem cell phenotype and targeting of HIF-1α may reduce or eliminate cancer stem cells.

Breast cancer is the most common form of cancer in women worldwide and affects 10% of the world's female population. 25% to 30% of patients with invasive breast cancer still die from this disease. The recurrence frequency of the disease varies between 60% and 80% within the first 3 years after treatment. In order to target breast cancer stem cells more effectively, in this study we aimed to reveal whether the hypoxic conditions in the tumor, which act as the stem cell production area, at the same time creates resistance to therapy. Thus, we evaluated effect of CSCs targeting agent Salinomycin alone or in combination with Everolimus which is an m-TOR and HIF-1α inhibitor on parental MCF-7 and MDA-231 breast cancer cells and their isolated CSCs in hypoxic conditions.

Here it is presented that starting with 2 mM, increased concentrations of salinomycin significantly inhibits proliferation and induce apoptosis in hypoxia, in both parental MCF-7 and MDA-231 breast cancer cells and in their isolated CSCs. The most effective concentration of salinomycin was 10 mM and induced around 35% and 45% of apoptosis in both parental MCF-7 and MDA-231 and their isolated CSCs, respectively. Whereas everolimus alone was not as effective as salinomycin, as 25 mM everolimus induced 30% and 15% of growth inhibition or apoptosis in both parental and CSCs of MCF-7 and MDA-231 cellsin hypoxia, respectively. When lower concentrations of salinomycin (2mM) and everolimus (5mM) was used in combination they show synergistic effect and able to inhibit proliferation at least 35% and 45% in both parental and CSCs of MCF-7 and MDA-231 cells in hypoxia, respectively. Similar results were also obtained for induction of apoptosis in response to salinomycin + everolimus treatment in hypoxia in both parental and CSCs of MCF-7 and MDA-231 cells. Hence using lower concentrations of salinomycin and everolimus together may provide an effective targeting strategy for hypoxic CSCs and may contribute to the development of novel strategies for therapeutic intervention in breast cancer.

Keywords: MCF-7,MDA-231, cancer stem cell, Salinomycin, Everolimus, hypoxia

How to Cite this Article

APA 6th edition
Pilevneli, H. & Eren, M.K. (2018). Effects of Salinomycin and Everolimus on Breast Cancer Stem Cells in Hypoxia . International Journal of Innovative Approaches in Science Research, 2(1), 25-40. doi: 10.29329/ijiasr.2018.132.3

Pilevneli, H. and Eren, M. (2018). Effects of Salinomycin and Everolimus on Breast Cancer Stem Cells in Hypoxia . International Journal of Innovative Approaches in Science Research, 2(1), pp. 25-40.

Chicago 16th edition
Pilevneli, Hatice and Mehtap Kilic Eren (2018). "Effects of Salinomycin and Everolimus on Breast Cancer Stem Cells in Hypoxia ". International Journal of Innovative Approaches in Science Research 2 (1):25-40. doi:10.29329/ijiasr.2018.132.3.

  1. Al Dhaheri Y., Attoub S., Arafat K., Abuqamar S., Eid A, Al Faresi N, Iratni R., 2013,    Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation,  Biochim Biophys Acta.  Apr;1830(4):3121-35. 22. [Google Scholar]
  2. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F., 2003, Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci U S A 100(7):3983-8. [Google Scholar]
  3. Alison, M. R., Murphy, G., and Leedham, S., 2008, Stem cells and cancer: a deadly mix, Cell Tissue Res 331(1):109-24. [Google Scholar]
  4. Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., and Wicha, M. S., Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia, Proc Natl Acad Sci U S A 109(8):2784-9. [Google Scholar]
  5. Dewangan Jayant, Srivastava Sonal, Rath Srikanta Kumar., 2017, Salinomycin: A new paradigm in cancer therapy. Tumor Biology 39 (3): 1-12  [Google Scholar]
  6. Ercan, C., van Diest, P. J., and Vooijs, M., 2011, Mammary development and breast cancer: the role of stem cells, Curr Mol Med 11(4):270-85. [Google Scholar]
  7. Gil, J., Stembalska, A., Pesz, K. A., and Sasiadek, M. M., 2008, Cancer stem cells: the theory and perspectives in cancer therapy, J Appl Genet 49(2):193-9. [Google Scholar]
  8. Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., and Lander, E. S., 2009, Identification of selective inhibitors of cancer stem cells by high-throughput screening, Cell 138(4):645-59. [Google Scholar]
  9. Hambardzumyan, D., Becher, O. J., and Holland, E. C., 2008, Cancer stem cells and survival pathways, Cell Cycle 7(10):1371-8. [Google Scholar]
  10. Hu, Y., and Fu, L., 2012, Targeting cancer stem cells: a new therapy to cure cancer patients, Am J Cancer Res 2(3):340-56. [Google Scholar]
  11. Iida, H., Suzuki, M., Goitsuka, R., and Ueno, H., 2011, Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2, Int J Oncol 40(1):71  [Google Scholar]
  12. Keith, B., and Simon, M. C., 2007, Hypoxia-inducible factors, stem cells, and cancer, Cell 129(3):465-72. [Google Scholar]
  13. Kilic M., Kasperczyk H., Fulda S., Debatin KM., 2007,  Role of hypoxia inducible factor-1 alpha in modulation of apoptosis  resistance, Oncogene 26 (14), 2027-2038. [Google Scholar]
  14. Kilic-Eren M., Boylu T., Tabor V., 2013, Targeting PI3 K/Akt represses hypoxia inducible factor-1alpha activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis, Cancer Cell Int 13 (1), 36.         [Google Scholar]
  15. Klonisch, T., Wiechec, E., Hombach-Klonisch, S., Ande, S. R., Wesselborg, S., Schulze-Osthoff, K., and Los, M., 2008, Cancer stem cell markers in common cancers - therapeutic implications, Trends Mol Med 14(10):450-60. [Google Scholar]
  16. Liang, D., Ma, Y., Liu, J., Trope, C. G., Holm, R., Nesland, J. M., and Suo, Z., 2012, The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells, BMC Cancer 12:201. [Google Scholar]
  17. Liu, S., and Wicha, M. S., 2010, Targeting breast cancer stem cells, J Clin Oncol 28(25):4006-12. [Google Scholar]
  18. Oak PS1, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, Wagner E, Knyazev P, Roidl A., 2012, Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer, 15;131(12):2808-19. [Google Scholar]
  19. Pires BR, DE Amorim ÍS, Souza LD, Rodrigues JA, Mencalha AL., 2016 Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and it’s Implication for CancerTreatment, Anticancer Res. ;36(11):5681-5691. [Google Scholar]
  20. Schwab, L. P., Peacock, D. L., Majumdar, D., Ingels, J. F., Jensen, L. C., Smith, K. D., Cushing, R. C., and Seagroves, T. N., 2012, Hypoxia-inducible factor 1alpha promotes primary tumor growth and tumor-initiating cell activity in breast cancer, Breast Cancer Res 14(1):R6. [Google Scholar]
  21. Semenza G. L., 2015, Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors, Clinical Science Sep 24, 129 (12) 1037-1045. [Google Scholar]
  22. Semenza, G. L., 2009, HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery, Curr Pharm Des 15(33):3839-43. [Google Scholar]
  23. Skog S, He Q, Khoshnoud R, Fornander T, Rutqvist LE. . 2004, Genes related to growth regulation, DNA repair and apoptosis in an oestrogen receptor-negative (MDA-231) versus an oestrogen receptor-positive (MCF-7) breast tumour cell line. Tumour BiolJan-Apr;25(1-2):41-7. [Google Scholar]